Instructor in Medicine, Massachusetts General Hospital
Internal Medicine
Dr. Eunice L. Kwak, MD
|
|
Give Review
Eunice Kwak is an expert in the field of Internal Medicine. She graduated from Duke University School of Medicine. Duke University School of Medicine is a top medical university. Duke University School of Medicine is ranked 8/29 in Research/PrimaryCare. Eunice L. Kwak has written publications. She has 53 publications published with PubMed. The lastest publication is: 'Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.' She accepts all Medicare patients.
Publications
- Predictors of Lymph Node Metastasis in Western Early Gastric Cancer.
- First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.
- Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
- Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic Cancer.
- Yttrium-90 Radioembolization as Salvage Therapy for Liver Metastases From Colorectal Cancer.
- First-in-Human Phase 1 Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors.
- Potent antitumor activity of Cabozantinib, a c-MET and VEGFR2 Inhibitor, in a Colorectal Cancer Patient-derived Tumor Explant Model.
- Adjuvant Therapy for Gastric Cancers: More Answers or More Questions?
- A Phase 1/2 and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed By Early Surgery for Resectable Pancreat...
- Mutational analysis and clinical correlation of metastatic colorectal Cancer.
- The Impact of Positive Margins on Outcome Among Patients With Gastric Cancer Treated With Radiation.
- Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangioCarcinoma.
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.
- Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2-Dependent and Other Solid Tumors.
- Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic Cancer.
- A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with...
- Mutational and Clinical Predictors of Pathologic Complete Response in the Treatment of Locally Advanced Rectal Cancer.
- Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic Cancer treated with intraoperative radiotherapy at the Mas...
- Phase 2 trial of afatinib, an ErbB family blocker, in solid Tumors genetically screened for target activation.
- Noncurative Gastrectomy for Gastric AdenoCarcinoma Should only be Performed in Highly Selected Patients.
- Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer.
- Targeted therapies with chemoradiation in esophageal Cancer: development and future directions.
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung Cancer: updated results from a phase 1 study.
- Pancreatic Ductal AdenoCarcinoma: Is There a Survival Difference for R1 Resections Versus Locally Advanced Unresectable Tumors? What Is a "True" R0 Resection?
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers.
- Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in CholangioCarcinoma Identified Through Broad-Based Tumor Genotyping.
- Rapid Radiographic and Clinical Improvement After Treatment of a MET-Amplified Recurrent Glioblastoma With a Mesenchymal-Epithelial Transition Inhibitor.
- MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric AdenoCarcinoma With Evidence of Responsiveness to Crizotinib.
- Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic Cancer.
- A phase 2 study of oral MKC-1, an inhibitor of importin-?, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic Cancer.
- Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Pat...
- Phase 1/2 study of everolimus in advanced hepatoCellular carcinoma.
- Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid Tumors.
- Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenoCarcinoma of the head.
- Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small Cell lung ca...
- Dose-painted Intensity-modulated Radiation Therapy for Anal Cancer: A Multi-institutional Report of Acute Toxicity and Response to Therapy.
- Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
- Anaplastic lymphoma kinase inhibition in non-small-cell lung Cancer.
- Clinical features and outcome of patients with non-small-cell lung Cancer who harbor EML4-ALK.
- Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatoCellular carcinoma: a phase II study.
- Case records of the Massachusetts General Hospital. Case 19-2009. A 63-year-old woman with Carcinoma of the gastroesophageal junction.
- NCCN Task Force Report: mTOR inhibition in solid Tumors.
- MDM2 promoter polymorphism and pancreatic Cancer risk and prognosis.
- Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic Cancer.
- Targeted agents: the rules of combination.
- Hereditary colorectal Cancer syndromes: an overview.
- Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenoCarcinomas.
- Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant.
- Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian Cancer.
- Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.
- Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic Cancer may not impact local control.
- Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.
Schools
Duke University
State University of New York At Buffalo
Brigham and Women39s Hospital
Dana FarberPartners
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Internal Medicine
Accepted Insurances
Education
-
Brigham and Women's Hospital -
Duke University School of Medicine
Hospital
-
Massachusetts General Hospital
Drug Facts
| NPI NUMBER | 1184605479 | |
| NPPES Provider LastName | KWAK | |
| NPPES Provider FirstName | EUNICE | |
| NPPES Provider ZIPCode | 021142621 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 299.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 43.0 | |
| Percent Opioid Claims | 14.38 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1184605479 |
| Last Name Of The Provider | KWAK |
| First Name Of The Provider | EUNICE |
| View All |
Similar Doctors
|
|
Dr. Cesar M. Castro, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leroy M. Parker, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Gabriel A. Brooks, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rachel A. Freedman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lipika Samal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Erica D. Bernstein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carla M. Oberst, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Maeve M. Mulvehill, MB |
|
|
Dr. Jordana L. Meyerson, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Adam Lerner, MD
This Doctor is OpenDoctor Recommended.
|